


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R<sup>1</sup> represents -C<sub>1-6</sub> alkyl-O-C<sub>1-6</sub> alkyl, -C<sub>3-8</sub> cycloalkyl, aryl, heterocyclyl, heteroaryl, -C<sub>1-6</sub> alkyl-aryl, -C<sub>1-6</sub> alkyl-heteroaryl, -C<sub>1-6</sub> alkyl-heterocyclyl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-aryl, -heteroaryl-X-heteroaryl, -heteroaryl-X-heterocyclyl, -heterocyclyl-X-aryl, -heterocyclyl-X-heteroaryl, or -heterocyclyl-X-heterocyclyl,

wherein said C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, aryl, heteroaryl, and heterocyclyl groups of R<sup>1</sup> may be optionally substituted by one or more (e.g. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, haloC<sub>1-6</sub> alkoxy, polyhaloC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup>, and/or -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, wherein R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together form a heterocyclic ring;

X represents a bond, O, CO, OCH<sub>2</sub>, CH<sub>2</sub>O, or SO<sub>2</sub>;

Z represents CO, CONR<sup>10</sup>, or SO<sub>2</sub>;

R<sup>10</sup> represents hydrogen, C<sub>1-6</sub> alkyl, -C<sub>3-8</sub> cycloalkyl, aryl, heterocyclyl, or heteroaryl;


— represents a single or a double bond;

m and n independently represent 0, 1, or 2;

R<sup>2</sup> represents hydrogen, C<sub>1-6</sub> alkyl, or C<sub>1-6</sub> alkoxy;

R<sup>3</sup> represents halogen, C<sub>1-6</sub> alkyl, hydroxy, C<sub>1-6</sub> alkoxy, cyano, amino, -CO-C<sub>1-6</sub> alkyl, -SO<sub>2</sub>C<sub>1-6</sub> alkyl, or trifluoromethyl;

R<sup>4</sup> represents -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>11</sup>R<sup>12</sup> or a group of formula (i):



wherein q is 2, 3, or 4;

-NR<sup>11</sup>R<sup>12</sup> represents a heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) R<sup>17</sup> groups;

R<sup>13</sup> represents C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl, -C<sub>1-6</sub> alkyl-C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkyl-C<sub>3-8</sub> cycloalkyl;

R<sup>14</sup> and R<sup>17</sup> independently represent halogen, C<sub>1-6</sub> alkyl, haloalkyl, OH, or C<sub>1-6</sub> alkoxy;

f is 0 or 1;

g is 1 or 2

k is 0, 1, or 2

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound as defined in claim 1 wherein R<sup>1</sup> represents:

-aryl optionally substituted by 1 or 2 halogen, haloC<sub>1-6</sub> alkyl, cyano or SO<sub>2</sub>Me groups;

-aryl-X-heterocyclyl;

-heteroaryl optionally substituted by 1 or 2 haloC<sub>1-6</sub> alkyl or cyano groups;

-heterocyclyl optionally substituted by 1 or 2 oxo groups; or

-C<sub>1-6</sub> alkyl-O-C<sub>1-6</sub> alkyl.

3. (Currently Amended) A compound as defined in claim 2 wherein R<sup>1</sup> represents tetrahydropyranyl, 4-cyanophenyl, 2-cyanopyridin-3-yl, or 2-trifluoromethylpyridin-3-yl.

4. (Original) A compound as defined in claim 3 wherein R<sup>1</sup> represents 4-cyanophenyl.

5. (Currently Amended) A compound as defined in any one of claims 1 to 4 claim 1 wherein X and Z both represent CO.

6. (Currently Amended) A compound as defined in any one of claims 1 to 5 claim 1 wherein — represents a single bond.

7. (Currently Amended) A compound as defined in any one of claims 1 to 6 claim 1 wherein m and n both represent 0.

8. (Currently Amended) A compound as defined in any one of claims 1 to 7 claim 1 wherein R<sup>4</sup> represents -(CH<sub>2</sub>)<sub>q</sub>-NR<sup>11</sup>R<sup>12</sup>, q represents 3 and -NR<sup>11</sup>R<sup>12</sup> represents N-piperidinyl or N-pyrrolidinyl optionally substituted by 1 or 2 C<sub>1-6</sub>

alkyl groups; or wherein R<sup>4</sup> represents a group of formula (i) wherein f and k both represent 0, g represents 2, and R<sup>13</sup> represents C<sub>1-6</sub> alkyl or C<sub>3-8</sub> cycloalkyl.

9. (Original) A compound as defined in claim 8 wherein R<sup>4</sup> represents a group of formula (i) wherein f and k both represent 0, g represents 2 and R<sup>13</sup> represents i-propyl.

10. (Original) A compound as defined in claim 1 which is:

4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;  
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}benzonitrile;  
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}pyridine;  
4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl} piperidine;  
1-{[4-(Methylsulfonyl)phenyl]carbonyl}-4-(4-{[3-(1-piperidinyl) propyl] oxy}phenyl) piperidine;  
1-{(4-Fluorophenyl)carbonyl}-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperidine;  
3-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}pyridine;  
4-{[4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}morpholine;  
1-(1-Piperidinylcarbonyl)-4-(4-{[3-(1-piperidinyl)propyl]oxy}phenyl)piperidine;  
4-(4-{[3-(1-Piperidinyl)propyl]oxy}phenyl)-1-(1-pyrrolidinylcarbonyl)piperidine;  
1-(4-Fluoro-phenyl)-1-{4-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-piperidin-1-yl}- methanone;  
1-(1-Methylethyl)-4-{[4-(1-{[4-(1-pyrrolidinylcarbonyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;  
1-(1-Methylethyl)-4-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-4-piperidinyl] phenyl}oxy)piperidine;  
1-(1-Methylethyl)-4-{[4-(1-{[4-(methylsulfonyl)phenyl]carbonyl}-4-piperidinyl)phenyl]oxy}piperidine;  
1-(1-Methylethyl)-4-{[(4-{1-[3-(methyloxy)propanoyl]}-4-piperidinyl) phenyl]oxy}piperidine;  
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl}pyridine;  
3-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl}pyridine;  
4-{[4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl]carbonyl} morpholine;  
1-(1-Azetidinylcarbonyl)-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperidine;  
1-(1-Methylethyl)-4-(4-{[1-(1-pyrrolidinylcarbonyl)-4-piperidinyl] phenyl}oxy)piperidine;

1-(1-Methylethyl)-4-({4-[1-(1-piperidinylcarbonyl)-4-piperidinyl]phenyl}oxy)piperidine;  
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-1-piperidinyl} carbonyl} thiomorpholine 1,1-dioxide;  
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy] phenyl}-1-piperidinyl)carbonyl] benzonitrile;  
1-Cyclobutyl-4-[(4-{1-[(4-fluorophenyl) carbonyl]-4-piperidinyl}phenyl) oxy] piperidine;  
1-Cyclobutyl-4-{{4-(1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-4-piperidinyl)phenyl}oxy}piperidine;  
1-Cyclobutyl-4-[(4-{1-[3-(methyloxy) propanoyl]-4-piperidinyl} phenyl)oxy] piperidine;  
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy] phenyl}-1-piperidinyl)carbonyl]pyridine;  
3-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperidinyl)carbonyl]pyridine;  
4-[(4-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-1-piperidinyl)carbonyl]morpholine;  
1-[(4-Fluorophenyl)carbonyl]-4-({3-(1-piperidinyl)propyl}oxy)phenyl)-1,2,3,6-tetrahydropyridine;  
4-{{4-(4-{{3-(1-Piperidinyl)propyl}oxy} phenyl)-3,6-dihydro-1(2H)-pyridinyl} carbonyl} benzonitrile;  
4-(4-{[3-(1-Piperidinyl)propyl] oxy}phenyl)-1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-1,2,3,6-tetrahydropyridine;  
4-(4-{[3-(1-Piperidinyl)propyl] oxy} phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;  
1-{{4-(Methylsulfonyl)phenyl}carbonyl}-4-({4-(3-(1-piperidinyl)propyl}oxy} phenyl)-1,2,3,6-tetrahydropyridine;  
4-{{4-(4-{{3-(1-Piperidinyl)propyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl} carbonyl} morpholine;  
1-(1-Piperidinylcarbonyl)-4-({4-(3-(1-piperidinyl)propyl}oxy}phenyl)-1,2,3,6-tetrahydropyridine;  
4-(4-{[3-(1-Piperidinyl)propyl]oxy} phenyl)-1-(1-pyrrolidinylcarbonyl)-1,2,3,6-tetrahydropyridine;  
1-[(4-Fluorophenyl)carbonyl]-4-({1-(1-methylethyl)-4-piperidinyl}oxy)phenyl)-1,2,3,6-tetrahydropyridine;  
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl}oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl} carbonyl}benzonitrile;  
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-{{4-(1-pyrrolidinylcarbonyl)phenyl}carbonyl}-1,2,3,6-tetrahydropyridine;  
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy} phenyl)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridine;  
4-(4-{[1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-{{4-(methylsulfonyl)phenyl}carbonyl}-1,2,3,6-tetrahydropyridine;

4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl]carbonyl}pyridine;  
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinyl]carbonyl)morpholine;  
4-(4-{{1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-(1-piperidinylcarbonyl)-1,2,3,6-tetrahydropyridine;  
4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-(1-pyrrolidinyl carbonyl)-1,2,3,6-tetrahydropyridine;  
4-{{4-[4-({3-[(2R)-2-Methyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-piperidinyl} carbonyl)benzonitrile;  
4-[4-({3-[(2R)-2-Methyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;  
4-[4-({3-[(2R,5R)-2,5-Dimethyl-1-pyrrolidinyl]propyl}oxy)phenyl]-1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidine;  
2-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} pyrazine;  
3-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} benzonitrile;  
1-(1-Methylethyl)-4-{{4-(1-{{4-(trifluoromethyl)phenyl]carbonyl}-4-piperidinyl)phenyl}oxy}piperidine;  
6-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl} quinoxaline;  
or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound as defined in claim 1 which is:  
5-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl}-2-pyridinecarbonitrile; and  
5-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl] oxy}phenyl)-1-piperidinyl]carbonyl}-2-(trifluoromethyl)pyridine;  
or a pharmaceutically acceptable salt thereof.

12. (Original) A compound as defined in claim 1 which is:  
4-{{4-(4-{{1-(1-Methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinyl] carbonyl} benzonitrile or a pharmaceutically acceptable salt thereof.

13. (Currently Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in ~~any one of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

14. (Cancelled).

15. (Cancelled).


16. (Cancelled).

17. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in ~~any one of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof.

18. (Cancelled).

19. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) preparing a compound of formula (I) wherein Z represents CO which comprises reacting a compound of formula (II)



or an optionally activated or protected derivative thereof, wherein ~~—~~, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m and n are as defined in claim 1, with a compound of formula R<sup>1</sup>-CO-L<sup>1</sup>, wherein R<sup>1</sup> is as defined in claim 1 and L<sup>1</sup> represents a suitable leaving group such as a suitable halogen atom, or a hydroxyl group; or

(b) preparing a compound of formula (I) wherein Z represents SO<sub>2</sub> which comprises reacting a compound of formula (II), with a compound of formula R<sup>1</sup>-SO<sub>2</sub>-L<sup>2</sup>, wherein R<sup>1</sup> is as defined in claim 1 and L<sup>2</sup> represents a suitable leaving group, such as a suitable halogen atom (eg. chlorine); or

(c) preparing a compound of formula (I) wherein Z represents CONH which comprises reacting a compound of formula (II), with a compound of formula R<sup>1</sup>-N=C=O, wherein R<sup>1</sup> is as defined in claim 1; or

(d) preparing a compound of formula (I) wherein Z represents CONR<sup>10</sup> which comprises reacting a compound of formula (II), with a compound of formula R<sup>1</sup>R<sup>10</sup>N-L<sup>3</sup>, wherein R<sup>1</sup> and R<sup>10</sup> are as defined in claim 1 and L<sup>3</sup> represents hydrogen or COCl; or

(e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(f) interconversion to other compounds of formula (I).